Janus Henderson Group PLC Buys 1,794,641 Shares of PepGen Inc. (NASDAQ:PEPG)

Janus Henderson Group PLC grew its stake in PepGen Inc. (NASDAQ:PEPG) by 331.2% during the 3rd quarter, HoldingsChannel reports. The fund owned 2,336,516 shares of the company’s stock after purchasing an additional 1,794,641 shares during the quarter. Janus Henderson Group PLC owned about 0.07% of PepGen worth $20,012,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Point72 DIFC Ltd purchased a new position in shares of PepGen in the 2nd quarter worth about $42,000. Allspring Global Investments Holdings LLC purchased a new position in PepGen in the third quarter worth about $95,000. Renaissance Technologies LLC bought a new position in shares of PepGen in the second quarter worth approximately $192,000. Marshall Wace LLP purchased a new stake in shares of PepGen during the second quarter valued at approximately $196,000. Finally, Rhumbline Advisers increased its position in shares of PepGen by 36.1% during the second quarter. Rhumbline Advisers now owns 18,853 shares of the company’s stock valued at $301,000 after acquiring an additional 5,002 shares in the last quarter. 58.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PEPG. Bank of America lowered their price objective on PepGen from $10.00 to $6.00 and set a “neutral” rating on the stock in a research report on Monday, November 18th. Wedbush dropped their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $26.00 target price on shares of PepGen in a research report on Friday, November 8th.

PepGen Trading Up 1.4 %

Shares of PEPG opened at $5.71 on Friday. The firm has a fifty day simple moving average of $6.85 and a two-hundred day simple moving average of $11.06. The firm has a market cap of $186.15 million, a PE ratio of -1.92 and a beta of 1.56. PepGen Inc. has a 1-year low of $4.00 and a 1-year high of $19.30.

PepGen Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.